To integrate these findings, we review and address methodological heterogeneity and variability in reporting regarding RCC WT1-targeted IHC in order to reconcile discrepancies and standardize evaluation of WT1 antigen expression, with the hope of better understanding the usefulness and possible clinical applications of this method in the management of aRCCs. This evidence concerns the gene WT1 and renal cell carcinoma.